Best Investments for
Acceleron says study of sotatercept reached its primary and secondary endpoints in placebo-controlled drug trial.
Investors respond to outbreak by backing pharmaceutical and medical diagnostic companies' shares No long-term financial benefit for big diversified Chinese drug makers from epidemic, Morningstar says
Jim Cramer says the impact of the coronavirus could crimp gains. From earnings to the economy, he has your game plan for next week.
The new year likely will be more of a stock-picker's market in which investors will need to be a bit more selective in order to generate outsized gains.
Antengene is working on cures for cancers with a disproportionally high prevalence among Chinese people, such as liver and T-cell blood cancer The Shanghai-based company is among dozens of start-ups founded in recent years by mainland Chinese returnees, typically scientists who spent decades in academia and with large drug companies in the United States
Jim Cramer accentuates the positive news in earnings, healthcare technology and the China trade deal.
Dow industrials jump as much as 206 points ahead of signing, then regroup as assessments are made Beyond tariffs, analysts note, numerous other issues continue to plague the US-China relationship
Pact includes Beijing's pledge to buy at least US$200 billion of American goods and services more than it did in 2017, over the course of two years In return, US is to reduce tariffs on some Chinese imports and cancel duties that were set to take effect in December
American executives briefed by White House officials say the agreement includes better intellectual property protection and progress on agriculture exports One business source says it is the first time 'we have something to applaud in the US-China relationship'
Investors in Direxion Shares Exchange Traded Fund Trust - Direxion Daily S&P Biotech Bull 3X Shares saw new options begin trading today, for the February 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the LABU options chain for the new February 28th contracts and identified one put and one call contract of particular interest.
Investors in Direxion Shares Exchange Traded Fund Trust - Daily S&P Biotech Bear 3X 2018 saw new options begin trading today, for the February 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the LABD options chain for the new February 28th contracts and identified one put and one call contract of particular interest.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF , we found that the implied analyst target price for the ETF based upon its underlying holdings is $123.66 per unit.
Hong Kong's role as a bridge between China and international markets, and as a fundraising hub for mainland firms, will only become stronger, says stock exchange chief executive Li rebuffed the view of some observers that seven months of violent social unrest has damaged the city's international reputation beyond repair
Incyte is cut to neutral from buy at Mizuho Securities USA after a Phase 3 trial of the biotech company's treatment for graft vs. host disease didn't meet its primary endpoint.
U.S. stock futures sink and oil prices surge after a U.S. military strike kills Gen. Qassem Soleimani, a top Iranian general; the U.S. economic calendar includes the ISM Manufacturing Index for December and minutes from the Federal Reserve's Dec. 10-11 meeting; Illumina abandons $1.2 billion acquisition of Pacific Biosciences.